Participation of underrepresented minority children in clinical trials for Fragile X syndrome and other neurodevelopmental disorders

Chechi Tasleem, Siyahian Salpi, Thairu Lucy, Randi J Hagerman, Lozano Reymundo

Research output: Contribution to journalArticle

Abstract

for participation in clinical trials (CTs) at the University of California Davis, MIND Institute. We conducted a cross-sectional survey in 100 participants (81 females and 19 males). The participants had high education levels (only 2% had not completed high school), a mean age of 44 years (SD±9.899) and had at least one child with a neurodevelopmental disorder. The diagnosis of Fragile X syndrome (FXS) had a significant association with past participation in CTs (p < 0.001). A statistical significance for age of diagnosis and participation in CTs was also found (z =.2.01, p = 0.045). The motivating factors were to help find cures/treatments for neurodevelopmental disorders and to relieve symptoms related to child's diagnosis. Factors explaining lack of participation, unwillingness to participate or unsure of participation were: lack of information/knowledge about the trials, time commitment to participation (screening, appointments, assessments, laboratory tests, etc.) and low annual household income. These results show that a portion of underrepresented minorities (URM) not participating in CTs are willing to participate and suggests that reducing barriers, particularly lack of knowledge/information and time commitment to trials are needed to improve recruitment.

Original languageEnglish (US)
Pages (from-to)147-152
Number of pages6
JournalIntractable and Rare Diseases Research
Volume3
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Fragile X Syndrome
Clinical Trials
Appointments and Schedules
Cross-Sectional Studies
Education
Neurodevelopmental Disorders
Therapeutics

Keywords

  • ASD
  • autism
  • clinical trials
  • Fragile X syndrome
  • health disparities
  • under represent minorities
  • URM

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Participation of underrepresented minority children in clinical trials for Fragile X syndrome and other neurodevelopmental disorders. / Tasleem, Chechi; Salpi, Siyahian; Lucy, Thairu; Hagerman, Randi J; Reymundo, Lozano.

In: Intractable and Rare Diseases Research, Vol. 3, No. 4, 2014, p. 147-152.

Research output: Contribution to journalArticle

@article{8909ae684d14491aaa5aadd83e7bddc2,
title = "Participation of underrepresented minority children in clinical trials for Fragile X syndrome and other neurodevelopmental disorders",
abstract = "for participation in clinical trials (CTs) at the University of California Davis, MIND Institute. We conducted a cross-sectional survey in 100 participants (81 females and 19 males). The participants had high education levels (only 2{\%} had not completed high school), a mean age of 44 years (SD±9.899) and had at least one child with a neurodevelopmental disorder. The diagnosis of Fragile X syndrome (FXS) had a significant association with past participation in CTs (p < 0.001). A statistical significance for age of diagnosis and participation in CTs was also found (z =.2.01, p = 0.045). The motivating factors were to help find cures/treatments for neurodevelopmental disorders and to relieve symptoms related to child's diagnosis. Factors explaining lack of participation, unwillingness to participate or unsure of participation were: lack of information/knowledge about the trials, time commitment to participation (screening, appointments, assessments, laboratory tests, etc.) and low annual household income. These results show that a portion of underrepresented minorities (URM) not participating in CTs are willing to participate and suggests that reducing barriers, particularly lack of knowledge/information and time commitment to trials are needed to improve recruitment.",
keywords = "ASD, autism, clinical trials, Fragile X syndrome, health disparities, under represent minorities, URM",
author = "Chechi Tasleem and Siyahian Salpi and Thairu Lucy and Hagerman, {Randi J} and Lozano Reymundo",
year = "2014",
doi = "10.5582/irdr.2014.01025",
language = "English (US)",
volume = "3",
pages = "147--152",
journal = "Intractable and Rare Diseases Research",
issn = "2186-3644",
publisher = "International Advancement Center for Medicine & Health Research Co., Ltd. (IACMHR Co., Ltd.)",
number = "4",

}

TY - JOUR

T1 - Participation of underrepresented minority children in clinical trials for Fragile X syndrome and other neurodevelopmental disorders

AU - Tasleem, Chechi

AU - Salpi, Siyahian

AU - Lucy, Thairu

AU - Hagerman, Randi J

AU - Reymundo, Lozano

PY - 2014

Y1 - 2014

N2 - for participation in clinical trials (CTs) at the University of California Davis, MIND Institute. We conducted a cross-sectional survey in 100 participants (81 females and 19 males). The participants had high education levels (only 2% had not completed high school), a mean age of 44 years (SD±9.899) and had at least one child with a neurodevelopmental disorder. The diagnosis of Fragile X syndrome (FXS) had a significant association with past participation in CTs (p < 0.001). A statistical significance for age of diagnosis and participation in CTs was also found (z =.2.01, p = 0.045). The motivating factors were to help find cures/treatments for neurodevelopmental disorders and to relieve symptoms related to child's diagnosis. Factors explaining lack of participation, unwillingness to participate or unsure of participation were: lack of information/knowledge about the trials, time commitment to participation (screening, appointments, assessments, laboratory tests, etc.) and low annual household income. These results show that a portion of underrepresented minorities (URM) not participating in CTs are willing to participate and suggests that reducing barriers, particularly lack of knowledge/information and time commitment to trials are needed to improve recruitment.

AB - for participation in clinical trials (CTs) at the University of California Davis, MIND Institute. We conducted a cross-sectional survey in 100 participants (81 females and 19 males). The participants had high education levels (only 2% had not completed high school), a mean age of 44 years (SD±9.899) and had at least one child with a neurodevelopmental disorder. The diagnosis of Fragile X syndrome (FXS) had a significant association with past participation in CTs (p < 0.001). A statistical significance for age of diagnosis and participation in CTs was also found (z =.2.01, p = 0.045). The motivating factors were to help find cures/treatments for neurodevelopmental disorders and to relieve symptoms related to child's diagnosis. Factors explaining lack of participation, unwillingness to participate or unsure of participation were: lack of information/knowledge about the trials, time commitment to participation (screening, appointments, assessments, laboratory tests, etc.) and low annual household income. These results show that a portion of underrepresented minorities (URM) not participating in CTs are willing to participate and suggests that reducing barriers, particularly lack of knowledge/information and time commitment to trials are needed to improve recruitment.

KW - ASD

KW - autism

KW - clinical trials

KW - Fragile X syndrome

KW - health disparities

KW - under represent minorities

KW - URM

UR - http://www.scopus.com/inward/record.url?scp=85010160380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010160380&partnerID=8YFLogxK

U2 - 10.5582/irdr.2014.01025

DO - 10.5582/irdr.2014.01025

M3 - Article

AN - SCOPUS:85010160380

VL - 3

SP - 147

EP - 152

JO - Intractable and Rare Diseases Research

JF - Intractable and Rare Diseases Research

SN - 2186-3644

IS - 4

ER -